Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

#4643

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Aim(s): We set out to characterise patients with early progression on PRRT.

Materials and methods: We conducted a multicentre (n=11) retrospective study and included all consecutive patients with advanced digestive NETs with RECIST 1.1 progression during PRRT (period: 2013-2021) or within 6 months after the last injection (P-group, n=48). We compared their baseline characteristics to those of control patients without progression (C-group, n=127) from 2 expert centres. In the P-group, we compared the time to progression (TTP) before and after PPRT, based on centralised RECIST 1.1 measurements.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,